Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory response
- 3 February 2009
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 87 (3) , 235-247
- https://doi.org/10.1007/s00109-009-0439-2
Abstract
The actors in the pathogenesis of diabetes and its complications are many and multifaceted. The effects of elevated levels of glucose are myriad; among these is the generation of advanced glycation end products (AGEs), the products of nonenzymatic glycoxidation of proteins and lipids. The finding that AGEs stimulate signal transduction cascades through the multiligand receptor RAGE unveiled novel insights into diabetes and its complications. Inextricably woven into AGE–RAGE interactions in diabetes is the engagement of the innate and adaptive immune responses. Although glucose may be the triggering stimulus to draw RAGE into diabetes pathology, consequent cellular stress results in release of proinflammatory RAGE ligands S100/calgranulins and HMGB1. We predict that once RAGE is engaged in the diabetic tissue, a vicious cycle of ligand–RAGE perturbation ensues, leading to chronic tissue injury and suppression of repair mechanisms. Targeting RAGE may be a beneficial strategy in diabetes, its complications, and untoward inflammatory responses.Keywords
This publication has 122 references indexed in Scilit:
- RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesisCarcinogenesis: Integrative Cancer Research, 2008
- RAGE and Modulation of Ischemic Injury in the Diabetic MyocardiumDiabetes, 2008
- RAGE Mediates Podocyte Injury in Adriamycin-induced GlomerulosclerosisJournal of the American Society of Nephrology, 2008
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetesMicrovascular Research, 2008
- S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathwayJournal of Leukocyte Biology, 2008
- Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– miceJournal of Clinical Investigation, 2008
- Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infectionCritical Care, 2007
- Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE) – an introductionMolecular Nutrition & Food Research, 2007
- Structural and functional insights into RAGE activation by multimeric S100BThe EMBO Journal, 2007
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996